Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Mylan Reveals FDA Goal Date For Bevacizumab
Mylan And Biocon Weighing Up A Third Biosimilar Launch
Mar 10 2020
•
By
Dean Rudge
Mylan's bevacizumab filing has been accepted for filing by the FDA • Source: Shutterstock
More from Biosimilars
More from Products